| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
|---|
| Outline of Final Research Achievements |
Herpes simplex virus (HSV), one of the neurotropic viruses, is impossible to cure latently infected nerve tissue because there is currently no vaccine that can prevent infection. Therefore, we aimed to establish a new treatment method by clarifying the importance and limitations of the defense mechanisms that are constructed in mucosal tissues, the site of HSV infection. In this study, we analyzed the details of the unresolved mechanism by which tissue-localized memory T cells (TRMs) accumulating in the mucosa completely inhibit the retrograde transport of HSV from the mucosa to the nerves.
|
